PGDx PlasmaSELECT 64 Panel

Personal Genome Diagnostics has launched its PlasmaSELECT 64 panel for pan-cancer tumor profiling. The CLIA-validated pan-cancer plasma assay incorporates the company's PARE and Digital Karyotyping technologies combined with VariantDX computational algorithms to identify sequence mutations with exceptional accuracy. The assay looks at genes shown to have biological and functional relevance to aid physicians making treatment decisions, and includes 15 unique biomarkers — 11 of which are associated with active clinical trials, the company said.